TY - JOUR
T1 - Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
AU - Polman, Chris H.
AU - Bertolotto, Antonio
AU - Deisenhammer, Florian
AU - Giovannoni, Gavin
AU - Hartung, Hans Peter
AU - Hemmer, Bernhard
AU - Killestein, Joep
AU - McFarland, Henry F.
AU - Oger, Joel
AU - Pachner, Andrew R.
AU - Petkau, John
AU - Reder, Anthony T.
AU - Reingold, Stephen C.
AU - Schellekens, Huub
AU - Sørensen, Per Soelberg
N1 - Funding Information:
The meeting was funded by Neutralizing Antibodies on Interferon-beta in Multiple Sclerosis (NABINMS) , a specific targeted research project of the 6th framework programme of the European Commission (contract no LSHB-CT-2005-018926 ). Volker Knappertz and Christoph Pohl (Bayer Schering Pharma), Bettina Stubinski (Merck Serono), Vijay Jethwa (Biogen Idec), and David Leppert (Novartis, at the time of the panel meeting) participated in the meeting and contributed to the discussion.
Funding Information:
With support from a 3-year collaborative contract provided by a Specific Targeted Research Project award of the 6th Framework Programme of the European Commission, the Neutralizing Antibodies on Interferon Beta in Multiple Sclerosis (NABINMS) consortium of European scientists and clinicians undertook a series of integrated scientific studies related to the generation and effect of NAbs to interferon-beta therapy used to treat MS. One aspect of the consortium's work was to produce a report and recommendations, based on data and expert opinion, concerning the clinical use of NAb titres, comparison of in-vivo and in-vitro measurements of NAb titres, and the clinical use of in-vivo measurements that might serve as predictors of the occurrence of NAbs. To develop consensus on these topics, the NABINMS consortium sponsored an international expert panel to discuss and debate data on NAbs and their practical consequences for the treatment of patients with MS who are receiving interferon beta.
PY - 2010/7
Y1 - 2010/7
N2 - The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy. In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta. The panel believed that information about NAbs and other markers of biological activity of interferons (ie, myxovirus resistance protein A [MxA]) can be integrated with clinical and imaging indicators to guide individual treatment decisions. In cases of sustained high-titre NAb positivity and/or lack of MxA bioactivity, a switch to a non-interferon-beta therapy should be considered. In patients who are doing poorly clinically, therapy should be switched irrespective of NAb or MxA bioactivity.
AB - The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy. In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta. The panel believed that information about NAbs and other markers of biological activity of interferons (ie, myxovirus resistance protein A [MxA]) can be integrated with clinical and imaging indicators to guide individual treatment decisions. In cases of sustained high-titre NAb positivity and/or lack of MxA bioactivity, a switch to a non-interferon-beta therapy should be considered. In patients who are doing poorly clinically, therapy should be switched irrespective of NAb or MxA bioactivity.
UR - http://www.scopus.com/inward/record.url?scp=77953454473&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(10)70103-4
DO - 10.1016/S1474-4422(10)70103-4
M3 - Comment/debate
C2 - 20610349
AN - SCOPUS:77953454473
SN - 1474-4422
VL - 9
SP - 740
EP - 750
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 7
ER -